American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

About this update from Jazz Pharmaceuticals Plc

[{"type":"text","content":"Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, March 24, 2026 /PRNewswire/ -- The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with these conditions, and empower them to feel confident, informed, and supported in their nutritional and health choices.","length":661,"tagName":"p"},{"type":"text","content":"People living with narcolepsy or IH experience disproportionately higher prevalence of CV and CM comorbidities, even at younger ages than may be expected.1,2 In these populations, sodium intake plays a clinically meaningful role in elevating blood pressure and increasing long-term CV risk, making proactive management of modifiable risk factors, such as sodium exposures from medications, important for this patient population.1,2","length":436,"tagName":"p"},{"type":"text","content":"Excess dietary sodium, including food, beverage, and prescription or Over-the-Counter medications, is a modifiable risk factor for hypertension and cardiovascular disease (CVD), a leading cause of death in the United States, accounting for approximately 700,000 deaths each year.3 The average American consumes upwards of 3,400 mg of sodium each day, which is nearly 50% above the recommended upper limit.4 Despite decades of evidence supporting sodium reduction as a key strategy to lower CV risk, sodium remains widely underrecognized as a modifiable risk factor, and awareness and adherence to a total daily recommended intake of 1,500 to 2,300 mg sodium remains a challenge, especially for people living with narcolepsy or IH.1,2","length":738,"tagName":"p"},{"type":"text","content":""The American Nutrition Association is dedicated to advancing the science of nutrition and translating that science into meaningfu...

More updates from Jazz Pharmaceuticals Plc